UAE Obesity Market Intelligence

    GLP-1 Market Research in the UAE: Obesity Prescribing, Access and Uptake

    BioNixus runs GLP-1 market research in the UAE for obesity brand, access and launch teams, combining prescriber surveys, payer interviews and patient persistence studies. Dubai is a field office for UAE. Cairo is the AMEA (APAC, Middle East, Africa) office.

    See the healthcare market research hub.

    In 2026 the question changed from whether patients will start a GLP-1 to which GLP-1, paid by whom, and for how long. The Emirates Drug Establishment approved Foundayo (orforglipron) on 3 April 2026, and the Emirates News Agency described the UAE as the second country to register it. Novo Nordisk launched the Wegovy pill in the UAE on 3 June 2026. Insurers still draw different lines on weight-management coverage. BioNixus measures that directly: who prescribes, what payers cover, what patients pay, and where they stop.

    Last reviewed: 29 October 2026

    Request a scoped proposalSee what we research

    $10,000–$60,000

    custom research

    82,000+

    physicians globally

    about 3,200

    physicians in the Middle East

    118 clients

    across 48 countries

    Quick answer

    GLP-1 market research UAE: what should a 2026 study cover?

    A useful 2026 study covers four things: who initiates GLP-1 therapy for weight management and why, how patients choose between injectable and oral options, what Thiqa, Daman and commercial plans actually reimburse, and how long patients stay on treatment once they pay. BioNixus runs these as commissioned primary research.

    • Prescriber surveysEndocrinologists, family physicians, bariatric specialists and aesthetic-clinic prescribers, in English and Arabic, on initiation, dose escalation, and stop and switch decisions.
    • Oral versus injectable choiceWhich patients move to Foundayo or the Wegovy pill, which stay on injectables, and why. Approval is not uptake.
    • Thiqa, Daman and commercial coverageAbu Dhabi Thiqa rules, Daman and other commercial plans, prior authorisation and self-pay boundaries by emirate.
    • Persistence and self-payMonthly spend tolerance, discontinuation triggers and clinic switching, across insured and self-pay cohorts.

    BioNixus recruits from 82,000+ physicians globally and about 3,200 physicians in the Middle East. Custom research is typically $10,000 to $60,000, and a scoped proposal is usually sent within 48 hours of a brief. BioNixus was founded in 2012 and has served 118 clients across 48 countries.

    Fit

    Who else to consider for a UAE GLP-1 question

    When the question isWho to brief
    Syndicated prescription and sales audits for GLP-1 volume trendsIQVIA. Choose BioNixus when you need the reasons behind prescribing, or a named-specialty or emirate cut.
    Consumer weight-management category sizingEuromonitor International. Choose BioNixus for prescriber and payer evidence.
    Syndicated UAE GLP-1 market sizing and forecastsGrand View Research. Choose BioNixus to split obesity from diabetes use with primary data.
    Consumer brand trackingKantar. Choose BioNixus for HCP and payer studies.
    OTC and retail measurementNielsenIQ. Choose BioNixus for prescription-only GLP-1 questions.
    In-market fieldwork by a local UAE healthcare agencyLocal agencies such as Sapience, IDS and Searchlight. Choose BioNixus for a combined prescriber, payer and patient design with a GCC roll-out.

    Names are plain text. This list is not a ranking. It describes the research type each name is known for, and it does not promise a result.

    Cited figures

    What changed in the UAE GLP-1 market in 2026

    • Oral GLP-1 approval. The Emirates Drug Establishment approved Foundayo (orforglipron) on 3 April 2026. The Emirates News Agency said the UAE was the second country to register it, and that it was expected to reach eligible patients from May 2026. Approval is not a count of prescriptions. Emirates News Agency, 3 April 2026
    • Wegovy pill launch. Novo Nordisk launched the Wegovy pill (oral semaglutide) in the UAE on 3 June 2026. CNBC described that launch as the first Wegovy pill market outside the United States. Pharmaceutical Commerce reported the same debut. Novo Nordisk announcement via ZAWYA, 3 June 2026
    • Disease burden. The Ministry of Health and Prevention’s National Health and Nutrition Survey 2024–2025 measured adult obesity at 22.4%. Pharmaceutical Commerce, citing Novo Nordisk’s 3 June 2026 release, reported that Novo said 28% of UAE adults live with obesity. Those are different methods. Do not average them into one launch forecast. Ministry of Health and Prevention, National Health and Nutrition Survey 2024–2025
    • Abu Dhabi coverage. On 11 June 2025 the Department of Health – Abu Dhabi published a Thiqa reimbursement policy for obesity medications (DoH/Policy/TRP-OMM/HPS/V1/2025). Eligible adults are 18 or older. Coverage uses BMI and listed complications: BMI 30 or above with a listed complication, or BMI 40 or above with none, and includes GLP-1 agonists. The same policy sets a check after four months on weight loss and activity. Daman and other commercial plans set their own rules, and many patients self-pay. NAVLIN Daily reported the policy on 12 June 2025; the policy text is the rule. Department of Health – Abu Dhabi, 11 June 2025
    • Market size, syndicated estimate, diabetes and obesity combined. Grand View Research’s UAE GLP-1 receptor agonist outlook puts revenue at US$257.2 million in 2025 and US$875.9 million by 2033 (15.3% CAGR, 2026–2033). Semaglutide had a 73.68% share in 2025, and tirzepatide is the fastest-growing product. That figure is not a BioNixus primary count of the weight-management share.

    Coverage

    What a BioNixus GLP-1 study in the UAE measures

    GLP-1 prescriber survey

    Quant and qual with endocrinologists, family physicians, bariatric specialists and aesthetic-clinic prescribers. Covers initiation triggers, dose escalation, and stop and switch decisions. Recruited from 82,000+ physicians globally and about 3,200 physicians in the Middle East. Specialist physician panel UAE

    Oral versus injectable choice

    Which patients prescribers move to Foundayo or the Wegovy pill, which stay on injectables, and why. Oral GLP-1 UAE market research

    Payer and coverage mapping

    Thiqa, Daman and commercial-plan criteria, prior authorisation and self-pay boundaries by emirate (Department of Health Abu Dhabi, Dubai Health Authority, and MOHAP or the Emirates Drug Establishment). Thiqa obesity reimbursement in Abu Dhabi

    Patient persistence and self-pay

    Monthly spend tolerance, discontinuation triggers and clinic switching, across insured and self-pay cohorts. Obesity patient journey research (GCC)

    Pharmacy and telehealth channel

    Dispensing practice, stocking and telehealth prescribing routes for GLP-1 medicines.

    GCC add-on cells

    The same instrument run in Saudi Arabia, Kuwait or Egypt. GCC obesity market

    Breakdown

    Obesity treatment categories we research in the UAE

    Oral and injectable GLP-1 therapy

    Foundayo (orforglipron), the Wegovy pill (oral semaglutide), and injectable incretin therapy. Commercial outcomes depend on who starts treatment, who switches, who pays, and who stays on it.

    Other prescription anti-obesity medication

    Established oral and injectable options that continue to serve cost-sensitive patients, intolerant patients, and prescribers working within tighter formulary or insurance constraints.

    Bariatric and metabolic surgery

    Sleeve gastrectomy, bypass, and revisional procedures in tertiary and private hospitals. Pharmacotherapy can substitute, delay, or sit beside surgery.

    Endoscopic and device-based interventions

    Intragastric balloons and endoscopic procedures positioned between pharmacotherapy and surgery, often offered to self-pay patients by private clinics.

    Clinic programmes and telehealth

    Multidisciplinary weight-management packages, remote prescribing and subscription coaching that compete with hospital metabolic programmes for the same patient.

    What is moving

    What is driving UAE GLP-1 and obesity research in 2026

    Two oral GLP-1 launches

    Foundayo was approved on 3 April 2026 and the Wegovy pill launched on 3 June 2026. Brand teams now need evidence on oral versus injectable choice, not only on whether a GLP-1 will be used.

    Coverage still differs by plan

    Abu Dhabi published a Thiqa obesity-medication policy on 11 June 2025. Daman and commercial plans apply their own rules. Many patients still self-pay.

    Diabetes and obesity use are mixed in syndicated sizing

    Grand View Research’s UAE GLP-1 outlook combines both uses. A weight-management forecast still needs primary research on the obesity share.

    Self-pay purchasing power

    A large share of weight-management treatment is paid directly by patients in private clinics. Initiation can be fast. Persistence is price sensitive.

    Surgery remains a competing route

    Bariatric and metabolic surgery is established in UAE hospitals, so a pharmacotherapy forecast has to account for substitution, delay and combined use.

    Emirate rules are not one market

    Dubai, Abu Dhabi and the northern emirates differ on insurance mandates, clinic density and what a patient will pay.

    Market structure

    How UAE GLP-1 access is structured

    The UAE obesity market runs on parallel funding tracks. Emirati nationals covered under Thiqa in Abu Dhabi follow a written obesity-medication policy. Expatriate residents on employer-funded plans, and patients paying entirely out of pocket, follow different rules. The same clinical profile can be covered in one setting and self-funded in another. A forecast has to model those tracks separately.

    Prescribing is not limited to hospital endocrinology. Endocrinologists, bariatric physicians, family physicians and aesthetic-clinic prescribers all initiate or refer, and dedicated weight-management clinics compete with hospital programmes and telehealth. A manufacturer cannot reach that base through hospital key accounts alone.

    Patients compare monthly cost, expected results and convenience across oral GLP-1s, injectables, surgery and clinic programmes, and they switch when cost or tolerability disappoints. Pharmacy stocking also shapes which product a patient ends up on. BioNixus studies this with prescribers, payers, pharmacists and patients.

    Signals

    Where obesity treatment demand concentrates in the UAE

    Dubai

    The densest private weight-management market, with DHA-regulated clinics, consumer marketing, high self-pay willingness and inbound interest. Dubai is a field office for UAE.

    Abu Dhabi

    A more structured payer environment. The Department of Health published the Thiqa obesity-medication policy on 11 June 2025, and Daman plans sit alongside tertiary hospital metabolic and bariatric programmes.

    Sharjah and the northern emirates

    A more price-sensitive mix, where treatment decisions hinge on affordability, pharmacy access and lower-cost clinic options.

    Al Ain and the Western Region

    Nationally weighted populations served by government-affiliated facilities, where covered pathways and specialist referral matter more than direct-to-consumer clinic marketing.

    Fieldwork

    Who we interview for a UAE GLP-1 study

    Endocrinologists and bariatric physicians

    Specialists who initiate and manage pharmacotherapy, set escalation and discontinuation thresholds, and refer into surgical pathways.

    Family physicians and aesthetic-clinic prescribers

    High-volume and clinic-based prescribers whose initiation triggers and product choice are not visible in a hospital key-account list.

    Payers and insurance medical directors

    People who set Thiqa, Daman and commercial-plan criteria, prior authorisation and the boundary between covered care and self-pay.

    Pharmacists and telehealth prescribers

    Dispensing and remote-prescribing routes that decide stocking, cash-pay presentation and where a patient is sent next.

    Patients, insured and self-pay

    People whose monthly spend tolerance and reasons for stopping determine the gap between a first prescription and sustained revenue.

    Dubai is a field office for UAE. Cairo is the AMEA (APAC, Middle East, Africa) office. The UK (London) is the Europe office. The USA (Sheridan, Wyoming) is the Americas office and global HQ. Al Khobar is a partner office for KSA. Kuwait is a field office for Kuwait. São Paulo is a field office for LATAM.

    Method

    How a UAE GLP-1 study is run

    • →Prescriber surveys and depth interviews with endocrinologists, family physicians, bariatric specialists and aesthetic-clinic prescribers, in English and Arabic, across Dubai, Abu Dhabi and the northern emirates.
    • →Payer interviews on Thiqa, Daman and commercial-plan criteria, prior authorisation and self-pay boundaries.
    • →Patient research on oral versus injectable choice, monthly spend and discontinuation, split between insured and self-pay cohorts.
    • →Pharmacy and telehealth channel work on stocking, dispensing and remote prescribing.
    • →Optional GCC add-on cells in Saudi Arabia, Kuwait or Egypt on the same instrument.
    • →Custom programmes typically price from $10,000 to $60,000. A scoped proposal is usually sent within 48 hours of a brief.

    Why BioNixus

    Why teams brief BioNixus for GLP-1 market research in the UAE

    BioNixus brings global reach with local rigour — operating across the Americas, EMEA, and APAC with the country-level depth that generic research cannot replicate. Founded in regulated healthcare, we apply the same methodological standards to life sciences (pharma, biotech, medtech) and to adjacent sectors including B2B, FMCG, and industrial markets. We translate KOL, payer, and hospital evidence — and where relevant, buyer, channel, and consumer insight — into launch, access, and growth strategies built for board-level scrutiny.

    • ✓The study is commissioned primary research: prescribers, payers and patients, not a resale of a syndicated GLP-1 outlook.
    • ✓Oral and injectable choice, Thiqa and Daman coverage, and persistence are measured in one design.
    • ✓Fieldwork is in English and Arabic across Dubai, Abu Dhabi and the northern emirates.
    • ✓Recruitment draws on 82,000+ physicians globally and about 3,200 physicians in the Middle East.
    • ✓Dubai is a field office for UAE, and Cairo is the AMEA (APAC, Middle East, Africa) office.
    • ✓Custom research is typically $10,000 to $60,000. BioNixus was founded in 2012 and has served 118 clients across 48 countries.

    Questions

    Frequently asked questions

    GLP-1 market research UAE: what should a 2026 study cover?

    A useful 2026 study covers four things: who initiates GLP-1 therapy for weight management and why, how patients choose between injectable and oral options, what Thiqa, Daman and commercial plans actually reimburse, and how long patients stay on treatment once they pay. BioNixus runs these as commissioned primary research with prescribers, payers, pharmacists and patients, recruited from 82,000+ physicians globally and about 3,200 physicians in the Middle East.

    Which agency can run a GLP-1 prescriber survey in the UAE?

    BioNixus runs GLP-1 prescriber surveys in the UAE with endocrinologists, family physicians, bariatric specialists and aesthetic-clinic prescribers, in English and Arabic, across Dubai, Abu Dhabi and the northern emirates. Dubai is a field office for UAE. Cairo is the AMEA (APAC, Middle East, Africa) office. Recruitment draws on 82,000+ physicians globally and about 3,200 physicians in the Middle East.

    Are GLP-1 medicines for weight management reimbursed in the UAE?

    Coverage depends on the plan and the emirate. On 11 June 2025 the Department of Health – Abu Dhabi published a Thiqa reimbursement policy for obesity medications. Eligible adults are 18 or older. Coverage uses BMI and listed complications: BMI 30 or above with a listed complication, or BMI 40 or above with none, and includes GLP-1 agonists. Daman and commercial plans apply their own rules, and many patients self-pay. A BioNixus payer study establishes the boundary for a specific product. The policy is summarised on Thiqa obesity reimbursement in Abu Dhabi.

    How do the 2026 oral GLP-1 launches change UAE research?

    The Emirates Drug Establishment approved Foundayo (orforglipron) on 3 April 2026. The Emirates News Agency described the UAE as the second country to register it and said it was expected to reach eligible patients from May 2026. Novo Nordisk launched the Wegovy pill in the UAE on 3 June 2026, reported as its first market outside the United States. Approval is not uptake: brand teams now need prescriber and patient evidence on oral versus injectable choice, switching and persistence. See oral GLP-1 UAE market research.

    How big is the UAE GLP-1 market?

    Grand View Research estimates UAE GLP-1 receptor agonist revenue at US$257.2 million in 2025, rising to US$875.9 million by 2033 (15.3% CAGR, 2026–2033), with semaglutide the largest product (73.68% share in 2025) and tirzepatide the fastest-growing. That figure covers diabetes and obesity use together, so a launch forecast still needs primary research on the weight-management share.

    How much does a UAE GLP-1 study cost?

    BioNixus custom research programmes typically price from $10,000 to $60,000, depending on sample, specialties, emirates and method. A scoped proposal is usually sent within 48 hours of a brief.

    Where is BioNixus UAE research delivered from?

    Dubai is a field office for UAE. Cairo is the AMEA (APAC, Middle East, Africa) office. The UK (London) is the Europe office. The USA (Sheridan, Wyoming) is the Americas office and global HQ. Al Khobar is a partner office for KSA. Kuwait is a field office for Kuwait. São Paulo is a field office for LATAM. BioNixus was founded in 2012 and has served 118 clients across 48 countries.

    Get a scoped proposal in 48 hours

    Name the brand, the country, and the breakdown your syndicated feed cannot give you. We send a project- and country-priced proposal — typically within 48 hours.

    Email us

    US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323